Latest News on ALEC

Financial News Based On Company


Advertisement
Advertisement

Weekly Recap: Q3 revenue and profit and siRNA target-marker reductions

https://www.tradingview.com/news/tradingview:4459f28b1fc9f:0-weekly-recap-q3-revenue-and-profit-and-sirna-target-marker-reductions/
Alector, Inc. (NASDAQ:ALEC) reported strong Q3 financial results, including $162.9 million in revenue and $124.6 million in net income, reversing a previous loss after the end of its collaboration with GSK. The company anticipates its funding will extend into the second half of 2029. Additionally, Alector announced positive primate study results for its siRNA programs AL164 and AL062, showing reductions in target markers across brain regions, with plans for first-in-human trials in Q2 2028.

Alector, Inc. (ALEC) stock price, news, quote and history

https://sg.finance.yahoo.com/quote/ALEC/
This page provides a snapshot of Alector, Inc. (ALEC) stock performance, including its current price, recent fluctuations, and key market data. The stock is listed on NasdaqGS and recently experienced an overnight increase after closing down on November 5th. Investors can find details on valuation, profitability, balance sheet, and a chart for historical data.

Alector (ALEC) Stock Price, Chart & Analysis

https://www.debelegger.nl/en/stock/ALEC.US
This article provides a detailed analysis of Alector (ALEC) stock, covering its current price, market capitalization, quality and value scores, and growth prospects. It highlights that Alector pays no dividend and has negative revenue and earnings growth in the last quarter, yet analysts expect future revenue growth. The company's balance sheet is strong with more cash than debt, but its overall "Belegger score" is weak.

Genentech gets global AL050 rights; Alector (ALEC) could earn up to $1.17B more in milestones.

https://www.stocktitan.net/sec-filings/ALEC/8-k-alector-inc-reports-material-event-effec2f5fccd.html
Alector (ALEC) has granted Genentech exclusive global rights to develop and commercialize AL050, a brain-penetrant GCase enzyme replacement therapy. Under the agreement, Alector received a $100 million upfront payment and is eligible for up to an additional $1.17 billion in milestone payments, plus tiered royalties on net sales. This deal, along with a recent $75 million underwritten offering, is expected to fund Alector's operations into the second half of 2029.

Alector Inc. (ALEC) Tops Q3 EPS by 132c

https://www.streetinsider.com/Earnings/Alector+Inc.+%28ALEC%29+Tops+Q3+EPS+by+132c/27301995.html
Alector Inc. (NASDAQ: ALEC) reported its Q3 earnings, significantly surpassing analyst expectations. The company announced an EPS of $1.11, which was $1.32 better than the analyst estimate of ($0.21). This strong performance indicates a positive quarter for Alector Inc.
Advertisement

Alector Reports Third Quarter 2026 Financial Results and Provides Business Update

https://www.globenewswire.com/news-release/2026/11/05/3397052/0/en/alector-reports-third-quarter-2026-financial-results-and-provides-business-update.html
Alector, Inc. reported strong third-quarter 2026 financial results, including a net income of $124.6 million, significantly up from a net loss in the prior year. The company announced a major exclusive global license agreement with Genentech for its AL050 program, involving a $100 million upfront payment and potential milestones of up to $1.17 billion. Alector also highlighted advancements in its ABC blood-brain barrier platform, with its lead program AL137 targeting first-in-human dosing by April 2027 and other siRNA programs (AL164, AL062) targeting first-in-human studies in Q2 2028, bolstering its financial position and neurodegeneration pipeline.

ALEC Q3'26 Earnings: revenue estimate is 2.19M USD

https://www.tradingview.com/news/tradingview:0e163c6f89c40:0-alec-q3-26-earnings-revenue-estimate-is-2-19m-usd/
Alector, Inc. (ALEC) is scheduled to release its Q3'26 earnings on November 10, with an estimated revenue of $2.19 million and an anticipated EPS of ($0.23) USD. The article provides a table detailing past reported and estimated revenue and EPS values, along with surprise percentages.

Alector, Inc. (ALEC) Seasonal returns chart

https://uk.finance.yahoo.com/quote/ALEC/seasonality/
This article presents a historical seasonality chart for Alector, Inc. (ALEC), displaying the average monthly price return from 2019 to 2026. It also provides current stock information, including the real-time Nasdaq price and after-hours trading data. The page is primarily a data visualization with minimal textual content, focusing on the seasonal performance of ALEC stock.

BTIG Maintains Alector(ALEC.US) With Buy Rating, Maintains Target Price $6

https://www.moomoo.com/news/post/1001158109/btig-maintains-alector-alecus-with-buy-rating-maintains-target-price
BTIG has reiterated its Buy rating for Alector (ALEC.US) and maintained its target price at $6. This indicates continued confidence from BTIG in Alector's stock performance and future prospects.

Four parties report the same 7.5M-share passive stake in Alector (ALEC).

https://www.stocktitan.net/sec-filings/ALEC/schedule-13g-alector-inc-passive-investment-disclosure-5-a87cb34126be.html
RA Capital Management, Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund have each reported a passive beneficial ownership of 7,500,000 shares, representing a 5.1% stake in Alector, Inc. (ALEC). This collective filing is based on the fund directly holding the shares, with voting and dispositive power delegated to RA Capital, its investment adviser. The 5.1% ownership calculation accounts for 111,656,919 shares outstanding as of July 31, 2026, and an additional 36,600,000 shares issued in a public offering that closed on October 19, 2026.
Advertisement

Alector, Inc. Estimates – NASDAQ:ALEC

https://www.tradingview.com/symbols/NASDAQ-ALEC/financials-estimates/
This page on TradingView provides financial estimates and data for Alector, Inc. (NASDAQ: ALEC). Users can explore reported financial data and analyst estimates across various financial statements, compare actual results with estimates, and visualize trends over time. The platform offers an overview of the company's financials, statements, statistics, estimates, dividends, earnings, and segments.

Alector: Maintaining 'Hold' ABC Platform Transition And GCase Partnership With Roche

https://seekingalpha.com/article/4955096-alector-stock-maintaining-hold-abc-platform-transition-and-gcase-partnership-with-roche
Alector maintains a "Hold" rating despite prior clinical setbacks and the termination of a GSK partnership. The company is now focusing on its ABC blood-brain barrier platform, with programs like AL137 for Alzheimer's and AL050 for Parkinson's, the latter benefiting from a significant partnership with Genentech/Roche. Key upcoming milestones include an IND filing for AL137 in Q1 2027 and first patient dosing by April 2027, with risks remaining if new initiatives do not succeed.

Alector Announces $75 Million Common Stock Offering

https://www.theglobeandmail.com/investing/markets/stocks/ALEC/pressreleases/8147715/alector-announces-75-million-common-stock-offering/
Alector (ALEC) announced an underwritten offering of 36.6 million shares of its common stock at $2.05 per share, aiming to raise approximately $75 million in gross proceeds. The offering, expected to close around October 19, 2026, involves participation from new and existing institutional investors. Alector plans to use the capital for general corporate purposes, including R&D, manufacturing, and potential acquisitions, to advance its neurodegeneration-focused pipeline.

Form 424B5 Alector Inc For: 17 October By Investing.com

https://ng.investing.com/news/stock-market-news/form-424b5-alector-inc-for-17-october-93CH-2741514
The article reports on the filing of Form 424B5 by Alector Inc. on October 17, 2026. This financial market update from Investing.com provides a brief notification of the regulatory filing, indicating it's a routine disclosure. It includes Alector Inc.'s stock symbol (ALEC) and its current performance (-3.16%).

Form 424B5 Alector Inc For: 17 October By Investing.com

https://in.investing.com/news/stock-market-news/form-424b5-alector-inc-for-17-october-93CH-5638343
This article announces the filing of Form 424B5 by Alector Inc. on October 17th. It includes general market data and related news headlines from Investing.com. The content primarily consists of market indices, commodity prices, and trending stocks.
Advertisement

Alector Enters Underwriting for 36.6M-Share, $2.05 Offering, Grossing $75 Million

https://www.tradingview.com/news/tradingview:5a20cbd6c9c9f:0-alector-enters-underwriting-for-36-6m-share-2-05-offering-grossing-75-million/
Alector (ALEC) has entered into an underwriting agreement with Morgan Stanley and BTIG for a public offering of 36,600,000 shares of common stock at $2.05 per share. This offering is expected to raise approximately $75.03 million in gross proceeds before fees and expenses. The transaction, made off an effective shelf registration, is anticipated to close on October 19, 2026, subject to customary conditions.

The stock offering from Alector (ALEC) is priced roughly 7.3% above its October 15 close.

https://www.stocktitan.net/sec-filings/ALEC/8-k-alector-inc-reports-material-event-54e9294fb191.html
Alector, Inc. (ALEC) has priced an underwritten offering of 36.6 million common shares at $2.05 per share, expecting to raise $75.03 million in gross proceeds. This price represents a 7.3% premium over the closing price on October 15, 2026. The proceeds will be used for general corporate purposes, including research, development, and manufacturing of product candidates.

Alector stock surges 13% on premium-priced equity offering

https://finance.yahoo.com/markets/stocks/articles/alector-stock-surges-13-premium-132631695.html
Alector shares surged approximately 13% in premarket trading after announcing a $75 million stock offering priced at a premium of about 7.3% above its previous closing price. The financing round saw participation from new and existing investors, with the proceeds intended for general corporate purposes including research, development, and potential acquisitions. Morgan Stanley and BTIG are jointly managing the offering for the biotechnology company.

Alector stock surges 13% on premium-priced equity offering

https://www.investing.com/news/stock-market-news/alector-stock-surges-13-on-premiumpriced-equity-offering-4954117
Alector stock surged 13% in premarket trading after announcing a $75 million stock offering priced at a premium. The biotechnology company priced 36.6 million shares at $2.05 each, a 7.3% premium over the previous day's closing price. The proceeds will be used for general corporate purposes, including research, development, and potential acquisitions.

Press Release: Alector Announces Pricing of Underwritten Offering

https://www.moomoo.com/news/post/1001439872/press-release-alector-announces-pricing-of-underwritten-offering
Alector, Inc. has announced the pricing of an underwritten public offering of its common stock. This offering is for 20,000,000 shares at a public offering price of $7.50 per share, aiming to raise gross proceeds of $150 million. The company has also granted underwriters an option to purchase an additional 3,000,000 shares.
Advertisement

Alector Announces Pricing of Underwritten Offering

https://www.wboc.com/online_features/press_releases/alector-announces-pricing-of-underwritten-offering/article_e5453ca4-86b9-5aa8-af61-18d3525917c9.html
Alector, Inc. announced the pricing of an underwritten public offering of 36,600,000 shares of its common stock at $2.05 per share, aiming to raise $75,030,000 in gross proceeds. The offering is expected to close around October 19, 2026, with proceeds intended for general corporate purposes, including research, development, and potential acquisitions. Morgan Stanley & Co. LLC and BTIG, LLC are acting as joint lead book-running managers for the offering.

Alector Announces Pricing of Underwritten Offering

https://www.globenewswire.com/news-release/2026/10/16/3382522/0/en/alector-announces-pricing-of-underwritten-offering.html
Alector, Inc. announced the pricing of an underwritten offering of 36,600,000 shares of common stock at $2.05 per share, aiming to raise $75,030,000.00 before expenses. The biotech company, focused on neurodegeneration therapies, expects to use the net proceeds for general corporate purposes including R&D and potential acquisitions. The offering, with participation from new and existing investors, is anticipated to close around October 19, 2026.

H.C. Wainwright raises Alector stock price target on platform progress By Investing.com

https://ng.investing.com/news/stock-market-news/hc-wainwright-raises-alector-stock-price-target-on-platform-progress-93CH-2738189
H.C. Wainwright increased its price target for Alector Inc. to $8.00 from $5.00, maintaining a Buy rating due to progress in its Alector Brain Carrier platform. This new target implies over 300% upside from the current stock price of $1.88. The firm highlighted promising candidates like AL137 and the Genentech license on AL050, as well as the siRNA platform's efficacy, despite the company's negative free cash flow.

H.C. Wainwright raises Alector stock price target on platform progress By Investing.com

https://ca.investing.com/news/stock-market-news/hc-wainwright-raises-alector-stock-price-target-on-platform-progress-93CH-4882776
H.C. Wainwright has increased its price target for Alector Inc. (NASDAQ:ALEC) from $5.00 to $8.00, maintaining a Buy rating, citing the company's progress with its Alector Brain Carrier platform and pipeline. This new target implies over 300% upside from the current stock price. The firm highlighted advancements like AL137, AL050 (licensed to Genentech), and siRNA platform candidates AL164 and AL062, while noting Alector's negative free cash flow of $158.39 million.

HC Wainwright & Co. maintains Buy rating on Alector, $8 price target

https://www.tradingview.com/news/tradingview:80cda27b7ed2e:0-hc-wainwright-co-maintains-buy-rating-on-alector-8-price-target/
HC Wainwright & Co. has reiterated its Buy rating on Alector's stock, setting an $8.00 price target. This target suggests a substantial 325.5% upside from the recent closing price. The firm highlighted Alector's strong pipeline of product candidates for neurodegenerative diseases and its innovative Alector Brain Carrier (ABC) Platform as key factors supporting the positive outlook.
Advertisement

Alector Price Target Raised to $8.00/Share From $5.00 by HC Wainwright & Co.

https://www.moomoo.com/news/post/1001196595/alector-price-target-raised-to-8-00-share-from-5
HC Wainwright & Co. has increased its price target for Alector to $8.00 per share, up from $5.00. This adjustment reflects an updated valuation by the analyst firm for the biotechnology company.

What Alector Bears Saw Before The Fall

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alec/alector/news/what-alector-bears-saw-before-the-fall
Alector (ALEC) shareholders experienced a 41.1% loss over the past year. Recent Q2 2026 results showed lower revenue but a narrowed loss, challenging the optimistic view for rapid growth and indicating that the bearish outlook, focusing on market size and dilution risk, was more accurate. The company's future now depends on its ABC brain shuttle platform and whether new assets like AL137 can successfully enter clinical trials and show biomarker proof.

Analyst raises Alector price target to $8 on neurodegenerative drug progress and Genentech deal

https://pluang.com/en/news-feed/alector-naikkan-target-harga-jadi-8-dolar-oleh-hc-wainwright
H.C. Wainwright has increased its price target for Alector (ALEC) from $5.00 to $8.00, maintaining a Buy rating. This adjustment is based on Alector's advancements in its neurodegenerative disease pipeline and a recent $100 million licensing deal with Genentech, which extends its financial runway until 2029. The deal could potentially yield an additional $1.17 billion in milestones and royalties, supporting Alector's strategic shift towards new therapeutic approaches.

HC Wainwright & Co. maintains Buy rating on Alector, $8 price target

https://www.tradingview.com/news/tradingview:8a86bca979391:0-hc-wainwright-co-maintains-buy-rating-on-alector-8-price-target/
HC Wainwright & Co. has reiterated its Buy rating for Alector (ALEC) with an $8.00 price target, suggesting a significant upside of 327.8% from its recent closing price. The positive outlook is attributed to Alector's strong pipeline of neurodegenerative disease therapies, supported by its ABC platform, and promising clinical developments including a strategic partnership with Genentech.

Options covering 2.42M shares held by the CEO are repriced by Alector (ALEC).

https://www.stocktitan.net/sec-filings/ALEC/8-k-alector-inc-reports-material-event-0554741b7111.html
Alector, Inc. (ALEC) has repriced employee stock options to $1.87 per share, effective October 13, 2026. This repricing impacts approximately 4.05 million shares, including 2.42 million shares held by CEO Arnon Rosenthal, whose original exercise prices ranged from $6.48 to $23.70. The move aims to retain and motivate employees, particularly as a majority of previous options were "underwater" (exercise price above market price), and avoids stock dilution or additional cash compensation.
Advertisement

Genentech pays $100m upfront for Alector’s AL050

https://longevity.technology/news/genentech-pays-100m-upfront-for-alectors-al050/
Genentech has acquired exclusive worldwide rights to Alector's Parkinson's drug, AL050, for an upfront payment of $100 million. The deal could include an additional $1.17 billion in milestone payments and royalties. AL050 is an enzyme replacement therapy designed to address GCase deficiency in Parkinson's disease, utilizing Alector's proprietary Brain Carrier technology to cross the blood-brain barrier.

Roundup: Shionogi Inc. Acquires IntraBio, Gate Bioscience extends Collaboration with Eli Lilly, Alector Enters Global License Agreement with Genentech

https://www.pharmexec.com/view/shionogi-inc-acquires-intrabio-gate-bioscience-extends-collaboration-eli-lilly-alector-license-genentech
This article details three significant deals in the biopharmaceutical industry: Shionogi Inc.'s acquisition of IntraBio for $2 billion, Gate Bioscience's expanded collaboration with Eli Lilly, potentially exceeding $870 million, and Alector's global licensing agreement with Genentech for its Al050 program, valued at up to $1.27 billion. These transactions highlight a trend of large pharmaceutical companies seeking external innovation to address the impending patent cliff and rejuvenate their pipelines, focusing on rare diseases, difficult-to-drug protein targets, and neurodegenerative conditions like Parkinson's and Niemann-Pick disease.

Alector and Genentech Ink $1.17B Global Licensing Deal for AL050

https://grafa.com/en/news/united-states/alector-genentech-global-licensing-agreement-al050
Alector has signed an exclusive global licensing agreement with Genentech for AL050, an investigational enzyme replacement therapy for Parkinson's disease. The deal includes a $100 million upfront payment and up to $1.17 billion in potential milestone payments, extending Alector's cash runway into 2029. Genentech will handle clinical development, regulatory activities, manufacturing, and commercialization, while Alector retains ownership of its Brain Carrier platform.

Alector shares up after sealing $1.27bn Roche Parkinson’s disease license deal

https://www.pharmaceutical-technology.com/news/alector-shares-up-after-sealing-1-27bn-roche-parkinsons-disease-license-deal/
Alector has entered into a licensing deal with Roche worth up to $1.27 billion for its Parkinson's disease candidate, AL050. This agreement grants Roche global rights to the preclinical drug, which uses Alector's blood-brain barrier delivery platform to address GCase deficiency. The deal marks a significant step for Roche in expanding its neurodegenerative disease pipeline and for Alector, which saw its shares surge following the announcement.

Alector Signs $1.27 Billion Genentech License Agreement for Parkinson’s Disease Program

https://finance.yahoo.com/healthcare/articles/alector-signs-1-27-billion-141333235.html
Alector has entered into a global licensing agreement with Genentech for its preclinical Parkinson's disease program, AL050, a brain-penetrant GCase enzyme replacement therapy. The deal includes an upfront payment of $100 million to Alector and potential milestone payments of up to $1.17 billion, along with tiered royalties on net sales. This agreement extends Alector's cash runway into 2029 and validates its Alector Brain Carrier (ABC) technology, which Alector retains for its other neurodegenerative programs.
Advertisement

A Parkinson’s drug deal could mean up to $1.17 billion for Alector if future goals are met.

https://www.stocktitan.net/news/ALEC/alector-enters-global-license-agreement-with-genentech-for-brain-nue0pg9z0nw3.html
Alector has entered into a global licensing agreement with Genentech for AL050, an investigational therapy for Parkinson's disease, receiving an upfront payment of $100 million. The agreement includes potential milestone payments of up to $1.17 billion and tiered royalties on net sales. This partnership is expected to extend Alector's cash runway into 2029, allowing it to advance its wholly-owned pipeline programs.

Genentech pens $1.27B deal to access Alector’s preclinical blood-brain barrier asset

https://www.biospace.com/deals/genentech-pens-1-27b-deal-to-access-alectors-preclinical-blood-brain-barrier-asset
Genentech has entered a deal worth up to $1.27 billion with Alector to acquire exclusive development and commercialization rights to Alector's preclinical asset, AL050. This asset utilizes Alector’s blood-brain barrier delivery platform to treat neurodegenerative diseases like Parkinson’s and Alzheimer’s. The partnership, which includes a $100 million upfront payment, provides Alector with a significant cash infusion, extending its runway and allowing it to advance other programs after previous clinical-stage setbacks.

Alector Enters Global License Agreement with Genentech for

https://www.globenewswire.com/news-release/2026/10/05/3374409/0/en/alector-enters-global-license-agreement-with-genentech-for-brain-penetrant-gcase-enzyme-replacement-therapy-for-parkinson-s-disease-and-other-neurodegenerative-diseases.html
Alector has entered into a global licensing agreement with Genentech for its AL050 program, a brain-penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and other neurodegenerative conditions. Alector will receive an upfront payment of $100 million and is eligible for up to $1.17 billion in milestone payments, plus tiered royalties on net sales. Genentech will handle development, regulatory, manufacturing, and commercialization, while Alector retains rights to its ABC platform for its wholly-owned pipeline, extending its cash runway into 2029.

Alector grants Genentech rights to GCase enzyme replacement therapy

https://www.bioworld.com/articles/734475-alector-grants-genentech-rights-to-gcase-enzyme-replacement-therapy?v=preview
Alector Inc. has granted Genentech Inc. exclusive global licensing rights for its AL-050 program, a brain-penetrant engineered glucocerebrosidase (GCase) enzyme replacement therapy. This preclinical therapy is aimed at neurological/psychiatric conditions. The agreement allows Genentech to develop and commercialize the program worldwide.

Alector surges on licensing agreement with Genentech ( (ALEC:NASDAQ)

https://seekingalpha.com/news/4650200-alector-surges-licensing-agreement-genentech
Alector's stock surged by approximately 22% after announcing a licensing agreement with Roche's Genentech. The deal grants Genentech global rights to develop and commercialize Alector's AL050 program, which targets Parkinson's and other neurodegenerative diseases. This partnership is expected to advance the research and potential treatment options for these conditions.
Advertisement

Genentech pays Alector $100M for preclinical Parkinson’s prospect

https://www.fiercebiotech.com/biotech/genentech-pays-alector-100m-preclinical-parkinsons-prospect
Genentech has paid Alector $100 million upfront for exclusive rights to AL050, a preclinical drug candidate for Parkinson's disease targeting neurodegeneration in patients with GBA mutations. The deal could reach up to $1.17 billion in milestones plus royalties, with Genentech taking on full development and commercialization responsibilities. This agreement significantly extends Alector's cash runway into 2029 and secures the future of AL050, which aims to address GCase deficiency.

Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases

https://finance.yahoo.com/healthcare/articles/alector-enters-global-license-agreement-110000587.html
Alector has signed a global licensing agreement with Genentech for AL050, its brain-penetrant GCase Enzyme Replacement Therapy for Parkinson’s disease and other neurodegenerative conditions. The deal includes a $100 million upfront payment and up to $1.17 billion in potential milestone payments, plus royalties. Genentech will handle development and commercialization, while Alector retains ownership of its proprietary blood-brain barrier delivery platform (ABC).

Inventory turnover of Alector, Inc. – HAN:0Z2

https://www.tradingview.com/symbols/HAN-0Z2/financials-statistics-and-ratios/invent-turnover/
The article focuses on the inventory turnover of Alector, Inc. (HAN:0Z2), a biotechnology company listed on the Hannover Stock Exchange. It provides financial data related to the inventory turnover for different periods, though specific values are not detailed in the provided text.

Total operating expenses of Alector, Inc. – HAN:0Z2

https://www.tradingview.com/symbols/HAN-0Z2/financials-income-statement/total-oper-expense/
This article provides a brief overview of Alector, Inc.'s total operating expenses, listed under the ticker HAN:0Z2 on the Hannover Stock Exchange. The current market status shows no trades. The content highlights the financial data available for the company.

Net income of Alector, Inc. – HAN:0Z2

https://www.tradingview.com/symbols/HAN-0Z2/financials-income-statement/net-income/
This article provides financial information for Alector, Inc. (0Z2) listed on the Hannover Stock Exchange. It focuses on the net income of the company and appears to be a stub or data-only page from TradingView, indicating that specific financial data would be presented for different periods.
Advertisement

Biotechnology Value Fund group discloses 8.4% stake in Alector (ALEC)

https://www.stocktitan.net/sec-filings/ALEC/schedule-13g-alector-inc-passive-investment-disclosure-5-8bcbfeb80fbf.html
The Biotechnology Value Fund (BVF) group, including affiliated entities and Mark N. Lampert, has reported an 8.4% passive beneficial stake in Alector, Inc. (ALEC) common stock. This stake represents 9,374,267 shares out of 111,656,919 shares outstanding as of July 31, 2026. The filing indicates shared voting and dispositive power among the reporting persons and their various entities.

Alector at Morgan Stanley conference: reset centers on brain delivery

https://www.investing.com/news/transcripts/alector-at-morgan-stanley-conference-reset-centers-on-brain-delivery-93CH-4901449
Alector (ALEC) announced a strategic shift at the Morgan Stanley Global Healthcare Conference, moving from a late-stage clinical company to a pre-clinical developer focused on its Alector Brain Carrier (ABC) platform. This pivot preserves its neurodegenerative disease mission despite setbacks in earlier approaches, with new programs targeting Alzheimer's, Parkinson's, and Lewy body dementia, supported by $170 million in cash projected to fund operations through 2027. The company emphasizes its de-risked portfolio based on human genetics and strong non-human primate data, with the lead asset AL137 expected to begin human dosing in Q2 2027.

Alector at Morgan Stanley conference: reset centers on brain delivery By Investing.com

https://uk.investing.com/news/stock-market-news/alector-at-morgan-stanley-conference-reset-centers-on-brain-delivery-93CH-4869486
Alector announced a strategic reset at the Morgan Stanley conference, shifting from a late-stage clinical company to a pre-clinical developer focused on its Alector Brain Carrier (ABC) platform for neurodegenerative diseases. The company plans to start dosing healthy volunteers for its lead asset, AL137, in Q2 2027 and believes its $170 million cash balance will fund operations through 2027 into proof-of-concept readouts. Alector emphasized its use of AI for efficiency, retention of core R&D capabilities, and potential partnerships for specific assets, while committing to advance AL137 independently through clinical proof of concept.

Don't Ignore The Insider Selling In Alector

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alec/alector/news/dont-ignore-the-insider-selling-in-alector
Alector Co-Founder, Arnon Rosenthal, recently sold US$193k worth of shares, though this was only 1.2% of his holding. While the sale occurred at the current stock price, which is not as concerning as a lower-priced sale, there has been no insider buying in the last year, suggesting caution. Insiders own 6.6% of Alector shares, valued at US$18m.

ALEC: Alector Inc Latest Stock Price, Analysis, News and Trading Ideas

https://stocktwits.com/symbol/ALEC
This article provides an overview of Alector Inc. (ALEC), a clinical-stage biopharmaceutical company focusing on immuno-neurology. It includes current stock price, market capitalization, key financial metrics, recent news, and investor sentiment. The company aims to develop treatments for degenerative brain disorders by repairing genetic mutations and rejuvenating immune cells.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement